Balyasny Asset Management L.P. Invests $200,000 in Inogen, Inc. (NASDAQ:INGN)

Balyasny Asset Management L.P. purchased a new position in Inogen, Inc. (NASDAQ:INGN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 21,855 shares of the medical technology company’s stock, valued at approximately $200,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. AlphaQuest LLC acquired a new stake in Inogen during the fourth quarter worth about $43,000. Meeder Asset Management Inc. bought a new stake in shares of Inogen during the 4th quarter worth approximately $56,000. Integrated Quantitative Investments LLC bought a new stake in shares of Inogen during the 4th quarter worth approximately $92,000. Ieq Capital LLC acquired a new stake in shares of Inogen during the 4th quarter worth approximately $94,000. Finally, Intech Investment Management LLC bought a new position in Inogen in the fourth quarter valued at approximately $94,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Trading Up 5.9%

Shares of Inogen stock opened at $6.09 on Monday. The firm’s 50 day moving average is $6.99 and its 200 day moving average is $8.79. The firm has a market capitalization of $163.74 million, a PE ratio of -2.71 and a beta of 1.63. Inogen, Inc. has a 1 year low of $5.70 and a 1 year high of $13.33.

Inogen (NASDAQ:INGN) last issued its earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.27. The firm had revenue of $82.28 million for the quarter, compared to analyst estimates of $79.57 million. Inogen had a negative net margin of 15.89% and a negative return on equity of 27.38%. As a group, research analysts anticipate that Inogen, Inc. will post -1.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on INGN shares. StockNews.com downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Stifel Nicolaus decreased their price target on Inogen from $10.00 to $7.00 and set a “hold” rating on the stock in a research note on Thursday, May 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Inogen in a report on Wednesday, April 9th.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.